FibroGen Inc. (FGEN) Has Soared To A New High On Phase 2 Study News

FibroGen Inc. (FGEN) announced after the bell Monday that its Phase 2 study of pamrevlumab in patients with idiopathic pulmonary fibrosis met the primary efficacy endpoint.

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>